Targeted Therapies in Metastatic Melanoma: Toward a Clinical Breakthrough?

Author(s): Fanny Julia, Luc Thomas, Charles Dumontet, Stephane Dalle

Journal Name: Anti-Cancer Agents in Medicinal Chemistry
(Formerly Current Medicinal Chemistry - Anti-Cancer Agents)

Volume 10 , Issue 9 , 2010

Become EABM
Become Reviewer
Call for Editor


Metastatic melanoma is a very aggressive cancer. Dacarbazine has been considered as the standard therapy for decades. Due to a better understanding of melanoma cells signalling and immunological response, new targeted therapies are now proposed. The efficency of these new drugs needs to be confirmed by on larger clinical trials. Ipilimumab (anti-CTLA4 monoclonal antibody) and V600-E- B-raf inhibitor have shown encouraging results, while c-KIT and MEK inhibitors are currently under evaluation. These recently published data shed the light on melanoma management. We review here the latest development of these molecules and the current perspectives in the treatment of metastatic melanoma.

Keywords: Melanoma, targeted therapy, ipilimumab, c-KIT inhibitor, B-raf inhibitor

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2010
Page: [661 - 665]
Pages: 5
DOI: 10.2174/187152010794479834
Price: $65

Article Metrics

PDF: 13